Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), has resulted in a pandemic that has had widespread …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Objectives We sought to investigate the efficacy and safety of SpikoGen®, a subunit
coronavirus disease 2019 (COVID-19) vaccine composed of a recombinant severe acute …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

Objective: This review was performed to compare the efficacy and safety among hospitalized
patients with COVID-19 who received baricitinib and those who received tocilizumab …

While a low vitamin D state has been associated with an increased risk of infection by SARS-
CoV-2 in addition to an increased severity of COVID-19 disease, a causal role is not yet …

Data supporting the use of Tocilizumab (TCZ) in COVID-19 are contrasting and inconclusive.
This meta-analysis aimed to assess TCZ effectiveness in reducing the mortality rate in …

Tocilizumab (TOC) is presumed to be an effective and safe treatment for severe COVID-19,
but its usefulness has not been yet investigated for different SARS-CoV-2 variants. This …

Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …